Combined Therapy Using Low-dose Gemcitabine and Cisplatin Chemotherapy and PD-1/PD-L1Antibody for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma: an Open-label, Multicenter, Single-arm Clinical Trial.

This document provides information about a clinical trial, NCT06567600, for the treatment of intrahepatic cholangiocarcinoma, a type of liver cancer. The trial aims to evaluate the effectiveness and safety of combining low-dose gemcitabine and cisplatin chemotherapy with the immune checkpoint inhibitor PD-1/PD-L1 antibody. The study is based on the hypothesis that low-dose chemotherapy can enhance the immune response to immunotherapy while minimizing side effects. The trial is not yet recruiting participants and is being conducted in China, with the Second Affiliated Hospital of Guangzhou Medical University as a collaborator. The primary completion date is December 31, 2027, and the contact person for the study is Ye Linsen. [Extracted from the article]